SCHEMBL4075648

SCHEMBL4075648

Cc1ccc(S(=O)(=O)c2nn(CC3CCNC3)c3ccccc23)cc1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SSTR4 P31391 1/20 0.40
TDO2 P48775 2/20 0.38
SYK P43405 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
KHK P50053 1/20 0.38
RXFP1 Q9HBX9 1/20 0.36
KDM1A O60341 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4070719 0.94 SYK (0.44) HTR6ALDH1A1HPGDMEN1KMT2A
SCHEMBL4071303 0.88 HTR6 (0.45) HTR6TDO2SYKKHK
SCHEMBL4071908 0.84 TDO2 (0.37) HTR6SSTR4TDO2SYKKHK
SCHEMBL4069379 0.81 HTR6 (0.48) HTR6ALDH1A1HPGDKDM4EKHK
SCHEMBL4818155 0.80 HTR6 (0.41) HTR6TDO2KHKKDM1A
SCHEMBL4077984 0.78 HTR6 (0.55) HTR6
SCHEMBL4815895 0.75 HTR6 (0.42) HTR6SYKKHK
SCHEMBL27630666 0.74 HTR6 (0.41) HTR6SYKKHK
SCHEMBL4066407 0.74 HTR6 (0.54) HTR6KMT2ARXFP1
SCHEMBL4076420 0.74 HTR6 (0.40) HTR6ALDH1A1MEN1KMT2ASSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589108-B2 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-09-15 US disclosed
US-20060030593-A1 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2006-02-09 US disclosed
US-6995176-B2 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2006-02-07 US disclosed
US-20040024023-A1 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030593-A1 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR3A, HTR5A HTR6 1/4885ALDH1A1 819/4885HPGD 1073/4885
US-20040024023-A1 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR3A, HTR1A HTR6 1/4885ALDH1A1 894/4885HPGD 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.